Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:ATP11A-CAPZA2

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: ATP11A-CAPZA2
	FusionPDB ID: 7706
	FusionGDB2.0 ID: 7706
		Hgene	Tgene
	Gene symbol	ATP11A	CAPZA2
	Gene ID	23250	830
	Gene name	ATPase phospholipid transporting 11A	capping actin protein of muscle Z-line subunit alpha 2
	Synonyms	ATPIH\|ATPIS	CAPPA2\|CAPZ
	Cytomap	13q34	7q31.2
	Type of gene	protein-coding	protein-coding
	Description	probable phospholipid-transporting ATPase IHATPase, class VI, type 11AP4-ATPase flippase complex alpha subunit ATP11Aphospholipid-translocating ATPasepotential phospholipid-transporting ATPase IH	F-actin-capping protein subunit alpha-2F-actin capping protein alpha-2 subunitcapZ alpha-2capping actin protein of muscle Z-line alpha subunit 2capping protein (actin filament) muscle Z-line, alpha 2epididymis secretory sperm binding protein
	Modification date	20200313	20200313
	UniProtAcc	Q6ZP68 Main function of 5'-partner protein:	P47755 Main function of 5'-partner protein: FUNCTION: F-actin-capping proteins bind in a Ca(2+)-independent manner to the fast growing ends of actin filaments (barbed end) thereby blocking the exchange of subunits at these ends. Unlike other capping proteins (such as gelsolin and severin), these proteins do not sever actin filaments.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000283558, ENST00000375630, ENST00000375645, ENST00000487903, ENST00000419448,	ENST00000466023, ENST00000490693, ENST00000361183, ENST00000458284,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	20 X 11 X 16=3520	8 X 5 X 7=280
	# samples	31	8
	** MAII score	log2(31/3520*10)=-3.50523530825042 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(8/280*10)=-1.8073549220576 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: ATP11A [Title/Abstract] AND CAPZA2 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: ATP11A [Title/Abstract] AND CAPZA2 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	ATP11A(113516889)-CAPZA2(116544231), # samples:1
Anticipated loss of major functional domain due to fusion event.	ATP11A-CAPZA2 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. ATP11A-CAPZA2 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. ATP11A-CAPZA2 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner

Gene

GO ID

GO term

PubMed ID

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr13:113516889/chr7:116544231)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across ATP11A (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across CAPZA2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000283558	ATP11A	chr13	113516889	+	ENST00000361183	CAPZA2	chr7	116544231	+	7903	3079	55	3720	1221
ENST00000283558	ATP11A	chr13	113516889	+	ENST00000458284	CAPZA2	chr7	116544231	+	4230	3079	55	3378	1107
ENST00000375630	ATP11A	chr13	113516889	+	ENST00000361183	CAPZA2	chr7	116544231	+	7903	3079	55	3720	1221
ENST00000375630	ATP11A	chr13	113516889	+	ENST00000458284	CAPZA2	chr7	116544231	+	4230	3079	55	3378	1107
ENST00000487903	ATP11A	chr13	113516889	+	ENST00000361183	CAPZA2	chr7	116544231	+	7903	3079	55	3720	1221
ENST00000487903	ATP11A	chr13	113516889	+	ENST00000458284	CAPZA2	chr7	116544231	+	4230	3079	55	3378	1107
ENST00000375645	ATP11A	chr13	113516889	+	ENST00000361183	CAPZA2	chr7	116544231	+	7903	3079	55	3720	1221
ENST00000375645	ATP11A	chr13	113516889	+	ENST00000458284	CAPZA2	chr7	116544231	+	4230	3079	55	3378	1107

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000283558	ENST00000361183	ATP11A	chr13	113516889	+	CAPZA2	chr7	116544231	+	0.000138359	0.9998616
ENST00000283558	ENST00000458284	ATP11A	chr13	113516889	+	CAPZA2	chr7	116544231	+	0.000308276	0.9996917
ENST00000375630	ENST00000361183	ATP11A	chr13	113516889	+	CAPZA2	chr7	116544231	+	0.000138359	0.9998616
ENST00000375630	ENST00000458284	ATP11A	chr13	113516889	+	CAPZA2	chr7	116544231	+	0.000308276	0.9996917
ENST00000487903	ENST00000361183	ATP11A	chr13	113516889	+	CAPZA2	chr7	116544231	+	0.000138359	0.9998616
ENST00000487903	ENST00000458284	ATP11A	chr13	113516889	+	CAPZA2	chr7	116544231	+	0.000308276	0.9996917
ENST00000375645	ENST00000361183	ATP11A	chr13	113516889	+	CAPZA2	chr7	116544231	+	0.000138359	0.9998616
ENST00000375645	ENST00000458284	ATP11A	chr13	113516889	+	CAPZA2	chr7	116544231	+	0.000308276	0.9996917

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ATP11A-CAPZA2

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
ATP11A	chr13	113516889	CAPZA2	chr7	116544231	3079	1008	FVFENTTVTSNGQVLITEHGDLGNGK

Top

Potential FusionNeoAntigen Information of ATP11A-CAPZA2 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

ATP11A-CAPZA2_113516889_116544231.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-B15:16	VTSNGQVLI	0.9642	0.6076	7	16
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C15:06	VTSNGQVLI	0.9973	0.7881	7	16
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C03:08	TVTSNGQVL	0.9854	0.867	6	15
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C03:19	TVTSNGQVL	0.984	0.983	6	15
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C03:07	TVTSNGQVL	0.9807	0.9695	6	15
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C01:17	TVTSNGQVL	0.7045	0.8825	6	15
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C08:13	TVTSNGQVL	0.6477	0.9008	6	15
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C08:04	TVTSNGQVL	0.6477	0.9008	6	15
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C08:03	TVTSNGQVL	0.3301	0.9799	6	15
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C01:30	TVTSNGQVL	0.2947	0.9087	6	15
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C16:01	VTSNGQVL	0.8873	0.9727	7	15
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C15:02	VTSNGQVLI	0.9976	0.698	7	16
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C15:05	VTSNGQVLI	0.9975	0.7835	7	16
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C03:03	TVTSNGQVL	0.9898	0.9839	6	15
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C03:04	TVTSNGQVL	0.9898	0.9839	6	15
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C03:17	TVTSNGQVL	0.9616	0.9576	6	15
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C03:05	TVTSNGQVL	0.9598	0.8964	6	15
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C01:03	TVTSNGQVL	0.7784	0.7945	6	15
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C03:06	TVTSNGQVL	0.7368	0.9837	6	15
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C01:02	TVTSNGQVL	0.7191	0.8791	6	15
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-B07:13	TVTSNGQVL	0.5213	0.7183	6	15
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-B35:13	TVTSNGQVL	0.4369	0.8302	6	15
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	HLA-C08:01	TVTSNGQVL	0.3301	0.9799	6	15

Top

Potential FusionNeoAntigen Information of ATP11A-CAPZA2 in HLA II

ATP11A-CAPZA2_113516889_116544231.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1401	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1401	SNGQVLITEHGDLGN	9	24
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1404	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1404	SNGQVLITEHGDLGN	9	24
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1426	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1426	SNGQVLITEHGDLGN	9	24
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1435	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1439	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1439	SNGQVLITEHGDLGN	9	24
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1454	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1454	SNGQVLITEHGDLGN	9	24
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1455	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1458	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1458	SNGQVLITEHGDLGN	9	24
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1460	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1460	SNGQVLITEHGDLGN	9	24
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1461	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1461	SNGQVLITEHGDLGN	9	24
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1462	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1470	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1471	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1471	SNGQVLITEHGDLGN	9	24
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1475	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1475	SNGQVLITEHGDLGN	9	24
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1482	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1486	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1486	SNGQVLITEHGDLGN	9	24
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1487	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1487	SNGQVLITEHGDLGN	9	24
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1488	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1488	SNGQVLITEHGDLGN	9	24
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1490	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1490	SNGQVLITEHGDLGN	9	24
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1497	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB1-1497	SNGQVLITEHGDLGN	9	24
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB3-0301	NTTVTSNGQVLITEH	4	19
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB4-0101	GQVLITEHGDLGNGK	11	26
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB4-0101	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB4-0103	GQVLITEHGDLGNGK	11	26
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB4-0103	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB4-0104	GQVLITEHGDLGNGK	11	26
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB4-0104	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB4-0106	GQVLITEHGDLGNGK	11	26
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB4-0106	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB4-0107	GQVLITEHGDLGNGK	11	26
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB4-0107	NGQVLITEHGDLGNG	10	25
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB4-0108	GQVLITEHGDLGNGK	11	26
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	3079	DRB4-0108	NGQVLITEHGDLGNG	10	25

Top

Fusion breakpoint peptide structures of ATP11A-CAPZA2

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
9744	TVTSNGQVLITEHG	ATP11A	CAPZA2	chr13	113516889	chr7	116544231	3079

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ATP11A-CAPZA2

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	9744	TVTSNGQVLITEHG	-7.9962	-8.1096
HLA-B14:02	3BVN	9744	TVTSNGQVLITEHG	-5.70842	-6.74372
HLA-B52:01	3W39	9744	TVTSNGQVLITEHG	-6.83737	-6.95077
HLA-B52:01	3W39	9744	TVTSNGQVLITEHG	-4.4836	-5.5189
HLA-A11:01	4UQ2	9744	TVTSNGQVLITEHG	-10.0067	-10.1201
HLA-A11:01	4UQ2	9744	TVTSNGQVLITEHG	-9.03915	-10.0745
HLA-A24:02	5HGA	9744	TVTSNGQVLITEHG	-6.56204	-6.67544
HLA-A24:02	5HGA	9744	TVTSNGQVLITEHG	-5.42271	-6.45801
HLA-B44:05	3DX8	9744	TVTSNGQVLITEHG	-7.85648	-8.89178
HLA-B44:05	3DX8	9744	TVTSNGQVLITEHG	-5.3978	-5.5112
HLA-A02:01	6TDR	9744	TVTSNGQVLITEHG	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of ATP11A-CAPZA2

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	6	15	TVTSNGQVL	ACTGTGACAAGCAACGGGCAGGTATTG
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	7	15	VTSNGQVL	GTGACAAGCAACGGGCAGGTATTG
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	7	16	VTSNGQVLI	GTGACAAGCAACGGGCAGGTATTGATA

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	10	25	NGQVLITEHGDLGNG	AACGGGCAGGTATTGATAACAGAACATGGCGACTTGGGAAATGGA
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	11	26	GQVLITEHGDLGNGK	GGGCAGGTATTGATAACAGAACATGGCGACTTGGGAAATGGAAAG
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	4	19	NTTVTSNGQVLITEH	AATACAACTGTGACAAGCAACGGGCAGGTATTGATAACAGAACAT
ATP11A-CAPZA2	chr13	113516889	chr7	116544231	9	24	SNGQVLITEHGDLGN	AGCAACGGGCAGGTATTGATAACAGAACATGGCGACTTGGGAAAT

Top

Information of the samples that have these potential fusion neoantigens of ATP11A-CAPZA2

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
LUAD	ATP11A-CAPZA2	chr13	113516889	ENST00000283558	chr7	116544231	ENST00000361183	TCGA-55-8620-01A

Top

Potential target of CAR-T therapy development for ATP11A-CAPZA2

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000283558

297_318

997

1135.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000283558

350_372

997

1135.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000283558

62_82

997

1135.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000283558

882_902

997

1135.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000283558

89_110

997

1135.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000283558

915_934

997

1135.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000283558

965_986

997

1135.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000375645

297_318

997

2857.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000375645

350_372

997

2857.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000375645

62_82

997

2857.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000375645

882_902

997

2857.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000375645

89_110

997

2857.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000375645

915_934

997

2857.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000375645

965_986

997

2857.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000487903

297_318

997

2878.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000487903

350_372

997

2878.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000487903

62_82

997

2878.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000487903

882_902

997

2878.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000487903

89_110

997

2878.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000487903

915_934

997

2878.0

Transmembrane

Helical

Hgene

ATP11A

chr13:113516889

chr7:116544231

ENST00000487903

965_986

997

2878.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to ATP11A-CAPZA2

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to ATP11A-CAPZA2

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)